Escitaloprám oxalate 10 mg
Pro Research Analysisby 
Searched over 200M research papers
Escitalopram Oxalate 10 mg: Pharmacokinetics, Bioequivalence, and Clinical Implications
Pharmacokinetics of Escitalopram Oxalate 10 mg
Escitalopram oxalate, a selective serotonin reuptake inhibitor (SSRI), is widely used for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). The pharmacokinetics of escitalopram oxalate 10 mg have been extensively studied in various populations. In a study involving healthy Chinese male volunteers, the maximum plasma concentration (Cmax) was found to be approximately 9.85 ng/ml, with a median time to reach maximum concentration (Tmax) of around 4.3 hours. The plasma elimination half-life (t1/2) was approximately 36.3 hours, indicating a relatively long duration of action . Another study confirmed similar pharmacokinetic parameters, with a Cmax of 38.00 µg/L and a Tmax of 3.1 hours in Chinese volunteers .
Bioequivalence of Escitalopram Oxalate Formulations
Bioequivalence studies are crucial for ensuring that different formulations of a drug provide the same therapeutic effect. Multiple studies have demonstrated the bioequivalence of various escitalopram oxalate formulations. For instance, a study comparing two 10 mg tablet formulations in Chinese volunteers found that the test and reference formulations were bioequivalent, with relative bioavailabilities of 105.1% and 104.9% for AUC0-∞ and AUC0-t, respectively . Similarly, another study involving Indian volunteers confirmed the bioequivalence of two commercial preparations of escitalopram oxalate 10 mg when co-administered with clonazepam, with no significant differences in pharmacokinetic parameters .
Clinical Efficacy and Safety
Escitalopram oxalate 10 mg has been shown to be effective in treating GAD and MDD. Pooled data from randomized controlled trials indicate that escitalopram significantly reduces anxiety symptoms as measured by the Hamilton Anxiety Scale (HAMA) score, with improvements observed as early as one to two weeks into treatment . Additionally, escitalopram is generally well-tolerated, with a predictable side effect profile that includes mild to moderate adverse events .
Adverse Effects and Special Considerations
While escitalopram is generally safe, there are reports of severe adverse effects. For example, a case study documented severe liver injury in a 16-year-old female patient treated with escitalopram oxalate 10 mg for anorexia nervosa. The patient developed significantly elevated liver enzymes, necessitating discontinuation of the drug and intensive liver-protective treatment . This highlights the importance of monitoring liver function in patients receiving escitalopram, especially those with pre-existing liver conditions.
Conclusion
Escitalopram oxalate 10 mg is a well-studied SSRI with established pharmacokinetics and proven bioequivalence across different formulations. It is effective in treating GAD and MDD, with a generally favorable safety profile. However, clinicians should be vigilant about potential severe adverse effects, such as liver injury, and monitor patients accordingly.
Sources and full results
Most relevant research papers on this topic